Preclinical Pharmacokinetics and Dosimetry of an
PET
anti-PDL1
dosimetry
pharmacokinetics
preclinical
zirconium-89
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
07
2021
accepted:
06
12
2021
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
18
2
2022
Statut:
epublish
Résumé
Anti-PDL1 is a monoclonal antibody targeting the programmed death-cell ligand (PD-L1) by blocking the programmed death-cell (PD-1)/PD-L1 axis. It restores the immune system response in several tumours, such as non-small cell lung cancer (NSCLC). Anti-PDL1 or anti-PD1 treatments rely on PD-L1 tumoural expression assessed by immunohistochemistry on biopsy tissue. However, depending on the biopsy extraction site, PD-L1 expression can vary greatly. Non-invasive imaging enables whole-body mapping of PD-L1 sites and could improve the assessment of tumoural PD-L1 expression. Pharmacokinetics (PK), biodistribution and dosimetry of a murine anti-PDL1 radiolabelled with zirconium-89, were evaluated in both healthy mice and immunocompetent mice with lung cancer. Preclinical PET (μPET) imaging was used to analyse [ Organ distribution was correctly estimated using PK modelling in both healthy mice and mice with lung cancer. Tumoural uptake occurred within 24 h post-injection of [ The predicted dosimetry was similar or lower than other antibodies radiolabelled with zirconium-89 for immunoPET imaging.
Identifiants
pubmed: 35174180
doi: 10.3389/fmed.2021.741855
pmc: PMC8841431
doi:
Types de publication
Journal Article
Langues
eng
Pagination
741855Informations de copyright
Copyright © 2022 Krache, Fontan, Pestourie, Bardiès, Bouvet, Payoux, Chatelut, White-Koning and Salabert.
Déclaration de conflit d'intérêts
Employment: CF and YB are employees of General Electric-Zionexa laboratory. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Immunol Res. 2017 Sep;5(9):767-777
pubmed: 28819064
Med Chem. 2011 Sep;7(5):389-94
pubmed: 21711221
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12369-74
pubmed: 20566862
J Proteomics. 2008 Jul 21;71(2):160-7
pubmed: 18617143
Nucl Med Biol. 2011 Jul;38(5):675-81
pubmed: 21718943
Ann Saudi Med. 2005 Jan-Feb;25(1):1-12
pubmed: 15822487
PLoS One. 2012;7(4):e35040
pubmed: 22545096
Annu Rev Med. 2002;53:89-112
pubmed: 11818465
BMC Med Imaging. 2016 Jun 18;16(1):41
pubmed: 27317478
Nucl Med Biol. 2013 May;40(4):451-7
pubmed: 23454247
Clin Transl Sci. 2018 Nov;11(6):540-552
pubmed: 29877608
Mol Imaging. 2019 Jan-Dec;18:1536012119829986
pubmed: 31044647
J Nucl Med. 2003 Aug;44(8):1282-3
pubmed: 12902419
Mol Pharm. 2018 Apr 2;15(4):1674-1681
pubmed: 29502426
Tumour Biol. 2012 Jun;33(3):607-15
pubmed: 22270450
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
J Clin Invest. 2020 Jul 1;130(7):3603-3620
pubmed: 32484460
J Clin Oncol. 2015 May 1;33(13):1491-504
pubmed: 25779566
Int J Cancer. 1992 Apr 1;50(6):912-7
pubmed: 1555890
Eur J Cancer. 2017 Apr;75:141-149
pubmed: 28222308
Drug Discov Today. 2006 Jan;11(1-2):81-8
pubmed: 16478695
J Clin Pathol. 2020 Oct;73(10):656-664
pubmed: 32591352
Jpn J Clin Oncol. 2014 Jun;44(6):515-25
pubmed: 24755547
J Pharmacokinet Biopharm. 1982 Apr;10(2):201-27
pubmed: 7120049
Med Phys. 2017 May;44(5):1707-1717
pubmed: 28207950
EJNMMI Res. 2017 Nov 3;7(1):88
pubmed: 29098485
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Paediatr Drugs. 2020 Apr;22(2):199-216
pubmed: 32052309
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32041818
J Thorac Dis. 2018 Feb;10(2):1124-1128
pubmed: 29607190
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Carcinog. 2013 Mar 16;12:6
pubmed: 23599688
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
J Nucl Med. 2015 May;56(5):778-83
pubmed: 25858044
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295
pubmed: 27573793
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120
pubmed: 28821924
Oncotarget. 2016 Mar 1;7(9):10215-27
pubmed: 26848870
J Nucl Med. 2005 Nov;46(11):1898-906
pubmed: 16269605
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Oncoimmunology. 2017 May 19;6(7):e1329071
pubmed: 28811971
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
J Nucl Med. 2009 Mar;50(3):477-84
pubmed: 19258258
Am J Nucl Med Mol Imaging. 2017 Sep 01;7(4):195-203
pubmed: 28913158
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Mol Oncol. 2010 Oct;4(5):397-403
pubmed: 20594926
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Nucl Med. 2009 Jun;50(6):974-81
pubmed: 19443585
Bone. 2003 Sep;33(3):387-98
pubmed: 13678781
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588
pubmed: 28653357
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
Clin Pharmacol Ther. 2008 Nov;84(5):548-58
pubmed: 18784655
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
Bioengineering (Basel). 2017 Sep 17;4(3):
pubmed: 28952557
Ann Pathol. 2018 Apr;38(2):110-125
pubmed: 29571563